J. Menezes

2.7k citations

24 papers · 544 indexed · 1 hit paper · h-index 11

Oncology top 5%
- Cancer Immunotherapy and Biomarkers 17
- CAR-T cell therapy research 10
- Lung Cancer Research Studies 4
Immunology
- Immunotherapy and Immune Responses 3
Pulmonary and Respiratory Medicine top 10%
- Lung Cancer Treatments and Mutations 9
- Lung Cancer Diagnosis and Treatment 2
Cancer Research
- Cancer Genomics and Diagnostics 2
Pathology and Forensic Medicine
Molecular Biology
- Melanoma and MAPK Pathways 4

Co-authors: F. Stephen Hodi Evan J. Lipson Stéphane Dalle Dirk Schadendorf Georgina V. Long Erika Castillo Gutiérrez Paolo A. Ascierto Luis Matamala
Cited by: Oncology Immunology Pulmonary and Respiratory Medicine
Journals: Journal of Clinical Oncology (14 papers)Cancer Research (1 paper)Annals of Oncology (4 papers)
Partner nations: United States Brazil France

In The Last Decade

J. Menezes

24 papers receiving 533 citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by J. Menezes

Since Specialization

Citations

This map shows the geographic impact of J. Menezes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Menezes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Menezes more than expected).

Fields of papers citing papers by J. Menezes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Menezes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Menezes. The network helps show where J. Menezes may publish in the future.

Co-authorship network

The 25 scholars most cited alongside J. Menezes, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with J. Menezes Line = papers co-authored together J. Menezes links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Nivolumab plus relatlimab in advanced melanoma: RELATIVITY-047 4-year update European Journal of Cancer ·Evan J. Lipson,F. Stephen Hodi,Hussein Tawbi,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Cristopher Lao,J. Menezes,Stéphane Dalle,Ana Arance,Caroline Gaudy‐Marqueste,Bingshu E. Chen,William T. Jackson,Sourav Mukherjee,Sonia Dolfi,Georgina V. Long	2025	1
2	200P Outcomes of patients (pts) with unfavourable, non-squamous cancer of unknown primary (CUP) progressing after induction chemotherapy (CTX) in the global, open-label, phase II CUPISCO study Annals of Oncology ·Tilmann Bochtler,A. Krämer,Chantal Pauli,Gonzalo Durán-Pacheco,Çağatay Arslan,Frédéric Bigot,Nasséra Chalabi,Natalie Cook,Antoîne Italiano,Ferrán Losa,J. Menezes,N. Ma,Mustafa Özgüroğlu,R.A. Pazo Cid,Jeffrey S. Ross,K-K. Shiu,P. Arni,H. Moch,Linda Mileshkin	2024	1
3	Five-year outcomes with first-line (1L) nivolumab + ipilimumab + chemotherapy (N + I + C) vs C in patients (pts) with metastatic NSCLC (mNSCLC) in CheckMate 9LA. Journal of Clinical Oncology ·Martin Reck,Tudor–Eliade Ciuleanu,Michael Schenker,Stéphanie Bordenave-Juchereau,Manuel Cobo,Óscar Juan,Niels Reinmuth,Eduardo Richardet,Enriqueta Felip,J. Menezes,Ying Cheng,Hideaki Mizutani,David P. Carbone,Shun Lü,Thomas John,Takekazu Aoyama,Javed Mahmood,Nan Hu,Laura J. Eccles,Luis Paz‐Ares	2024	6
4	Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047 Journal of Clinical Oncology ·Hussein A. Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Barbara Ratto,Saima Rodriguez,Antonella Mazzei,Sonia Dolfi,Georgina V. Long	2024	24
5	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma (RELATIVITY-047): Overall survival (OS) and melanoma-specific survival (MSS) outcomes at 3 years. Journal of Clinical Oncology ·Hussein A. Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Barbara Ratto,Saima Rodriguez,Antonella Mazzei,Sonia Dolfi,Georgina V. Long	2024	7
6	Subcutaneous (SC) nivolumab (NIVO) vs intravenous (IV) NIVO in patients with previously treated advanced or metastatic clear cell renal cell carcinoma (ccRCC): Safety and patient-reported outcomes (PROs) of the randomized phase 3 CheckMate 67T trial. Journal of Clinical Oncology ·María T. Bourlon,Laurence Albigès,Matías Chacón,Hernán Cutuli,José Maurício Mota,Ignacio Magrí,Mauricio Burotto,Murilo Luz,J. Menezes,Eduardo Patricio Yanez Ruiz,Marco Maruzzo,Sergio Bracarda,Dhanrajsinh Rathod,Zhuoxin Yu,Balmeet Gurm,Matthew Dixon,Saby George	2024	2
7	LBA1 Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III NSCLC: Final results from PACIFIC-2breakdown → ESMO Open ·Jeffrey D. Bradley,Shunichi Sugawara,K.H. Lee,Gyula Ostoros,Ahmet Demirkazık,Milada Zemanová,Virote Sriuranpong,Ana Caroline Zimmer Gelatti,J. Menezes,Bogdan Żurawski,Michael Newton,P. Chander,Nan Jia,Zofia F. Bielecka,Mustafa Özgüroğlu	2024	37
8	Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047. Journal of Clinical Oncology ·Hussein A. Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Barbara Ratto,Saima Rodriguez,Yuanfang Xu,Sonia Dolfi,Georgina V. Long	2023	7
9	LBA16 Primary analysis of efficacy and safety in the CUPISCO trial: A randomised, global study of targeted therapy or cancer immunotherapy guided by comprehensive genomic profiling (CGP) vs platinum-based chemotherapy (CTX) in newly diagnosed, unfavourable cancer of unknown primary (CUP) Annals of Oncology ·Linda Mileshkin,Tilmann Bochtler,Chantal Pauli,Gonzalo Durán-Pacheco,Çağatay Arslan,Frédéric Bigot,Nasséra Chalabi,Natalie Cook,Antoîne Italiano,Ferrán Losa,J. Menezes,Coralie Michaud,Mustafa Özgüroğlu,Roberto Pazo-Cid,Jeffrey S. Ross,K-K. Shiu,Michael Stahl,M. Thomas,Holger Moch,A. Krämer	2023	11
10	First-line (1L) nivolumab (N) + ipilimumab (I) + chemotherapy (C) vs C alone in patients (pts) with metastatic NSCLC (mNSCLC) from CheckMate 9LA: 4-y clinical update and outcomes by tumor histologic subtype (THS). Journal of Clinical Oncology ·David P. Carbone,Tudor–Eliade Ciuleanu,Michael Schenker,Manuel Cobo,Stéphanie Bordenave-Juchereau,Óscar Juan,J. Menezes,Niels Reinmuth,Eduardo Richardet,Ying Cheng,Hideaki Mizutani,Luis Paz‐Ares,Shun Lu,Thomas John,Xiaoqing Zhang,Nan Hu,David Balli,Vipul Baxi,Jaclyn Neely,Martin Reck	2023	6
11	First-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients (pts) with metastatic non–small cell lung cancer (NSCLC): 3-year update from CheckMate 9LA. Journal of Clinical Oncology ·Luis Paz‐Ares,Tudor–Eliade Ciuleanu,Manuel Cobo,Jaafar Bennouna,Ying Cheng,Hideaki Mizutani,Alejo Lingua,Felipe Reyes,Niels Reinmuth,J. Menezes,Jacek Jassem,Светлана Проценко,Kynan Feeney,Emmanuel de la Mora Jimenez,Shun Lü,Thomas John,David P. Carbone,Xiaoqing Zhang,Nan Hu,Martin Reck	2022	19
12	Olaparib plus abiraterone as first-line therapy in men with metastatic castration-resistant prostate cancer: Pharmacokinetics data from the PROpel trial. Journal of Clinical Oncology ·Andrew J. Armstrong,Noel W. Clarke,Antoine Thiery-Vuillemin,Mototsugu Oya,Giuseppe Procopio,J. Menezes,Gustavo Girotto,Pooja Ghatalia,Franco Nolè,Omar Din,Philipp Spiegelhalder,I. Minčík,Robbert J. van Alphen,Nicolaas Lumen,Christian Hosius,Diansong Zhou,Laura Barker,Melanie Dujka,Fred Saad	2022	2
13	Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047. Journal of Clinical Oncology ·Hussein A. Tawbi,F. Stephen Hodi,Evan J. Lipson,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Pamela Salman,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Sarah Keidel,Karin Jonczak,Anne Marie Sobiesk,Sonia Dolfi,Georgina V. Long	2022	10
14	1036O Relatlimab (RELA) + nivolumab (NIVO) vs. NIVO in previously untreated metastatic or unresectable melanoma: Additional efficacy in RELATIVITY-047 Annals of Oncology ·F. Stephen Hodi,Hussein A. Tawbi,Evan J. Lipson,Dirk Schadendorf,P.A. Ascierto,Luis Matamala,Eric Gutierrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Laurence Toms,K Jonczak,A.M. Sobiesk,Georgina V. Long	2021	4
15	OA03.02 Nivolumab (NIVO) + ipilimumab (IPI) + 2 Cycles of Platinum-Doublet Chemotherapy (Chemo) vs. 4 Cycles Chemo as First-Line (1L) Treatment) for Stage IV/Recurrent Non-Small Cell Lung Cancer (NSCLC): CheckMate 9LA Journal of Thoracic Oncology ·Martin Reck,Tudor–Eliade Ciuleanu,(unknown),Michael Schenker,Bogdan Żurawski,J. Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,(unknown),Aurelia Alexandru,Hiroshi Sakai,Arnaud Scherpereel,Shun Lu,Thomas John,David P. Carbone,S. Meadows–Shropshire,Jiarui Yan,Luis Paz‐Ares	2021	1
16	First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA. Journal of Clinical Oncology ·Martin Reck,Tudor–Eliade Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan Żurawski,J. Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,Óscar Juan,Aurella Alexandru,Hiroshi Sakai,Arnaud Scherpereel,Shun Lu,Luis Paz‐Ares,David P. Carbone,Arteid Memaj,S. Marimuthu,Phuong Tran,Thomas John	2021	13
17	98O First-line nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles chemotherapy (chemo) vs 4 cycles chemo in advanced non-small cell lung cancer (aNSCLC): Association of blood and tissue tumor mutational burden (TMB) with efficacy in CheckMate 9LA Journal of Thoracic Oncology ·Luis Paz‐Ares,T-E. Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan Żurawski,J. Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,Óscar Juan,Aurelia Alexandru,Hiroshi Sakai,Arnaud Scherpereel,Martin Reck,S. Lu,Thomas John,S. Meadows–Shropshire,David Balli,Sachin Agrawal,David P. Carbone	2021	14
18	Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047). Journal of Clinical Oncology ·Evan J. Lipson,Hussein Tawbi,Dirk Schadendorf,Paolo A. Ascierto,Luis Matamala,Erika Castillo Gutiérrez,Piotr Rutkowski,Helen Gogas,Christopher D. Lao,J. Menezes,Stéphane Dalle,Ana Arance,Jean‐Jacques Grob,Shivani Srivastava,Mena Abaskharoun,Katy L. Simonsen,Bin Li,Georgina V. Long,F. Stephen Hodi	2021	118
19	LBA59 First-line nivolumab (NIVO) + ipilimumab (IPI) combined with 2 cycles of platinum-based chemotherapy (chemo) vs 4 cycles of chemo in advanced non-small cell lung cancer (NSCLC): Patient-reported outcomes (PROs) from CheckMate 9LA Annals of Oncology ·Martin Reck,T-E. Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan Żurawski,J. Menezes,Eduardo Richardet,Jaafar Bennouna,Ying Cheng,Luis Paz‐Ares,Sheng-Feng Lu,Thomas John,Brad Padilla,Xiaowu Sun,A. Moisei,Jiarui Yan,Yong Yuan,Steven I. Blum,David P. Carbone	2020	5
20	Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA. Journal of Clinical Oncology ·Martin Reck,Tudor–Eliade Ciuleanu,Manuel Cobo,Michael Schenker,Bogdan Żurawski,J. Menezes,Eduardo Richardet,Jaafar Bennouna,Enriqueta Felip,Óscar Juan,Aurella Alexandru,Hiroshi Sakai,Arnaud Scherpereel,Shun Lu,Thomas John,David P. Carbone,S. Meadows–Shropshire,Jinchun Yan,Luis Paz‐Ares	2020	101

About J. Menezes

J. Menezes is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Oral Surgery, having authored 24 papers that have together received 544 indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (17 papers), CAR-T cell therapy research (10 papers), Lung Cancer Treatments and Mutations (9 papers), Lung Cancer Research Studies (4 papers), Melanoma and MAPK Pathways (4 papers), Immunotherapy and Immune Responses (3 papers), Lung Cancer Diagnosis and Treatment (2 papers) and Cancer Genomics and Diagnostics (2 papers). The work is most often cited by research in Oncology (469 citations), Immunology (165 citations) and Pulmonary and Respiratory Medicine (227 citations). J. Menezes has collaborated with scholars based in United States, Brazil and France. Frequent co-authors include F. Stephen Hodi, Evan J. Lipson, Stéphane Dalle, Dirk Schadendorf, Georgina V. Long, Erika Castillo Gutiérrez, Paolo A. Ascierto, Luis Matamala, Piotr Rutkowski and Jean‐Jacques Grob. Their work appears in journals such as Journal of Clinical Oncology, Cancer Research and Annals of Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact